Quantcast

Latest C-Met Stories

2008-10-22 06:00:08

Exelixis, Inc. (Nasdaq:EXEL) today reported interim data from a phase 1 dose-escalation trial of XL147, a novel small molecule inhibitor of phosphoinositide-3 kinase (PI3K), which is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. The trial is enrolling patients with metastatic or unresectable solid tumors for which known effective measures do not exist or are no longer effective. The trial is being conducted at Vall D'Hebron University...

2008-09-24 12:00:37

Aveo Pharmaceuticals has initiated a Phase I clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105, its novel, highly potent antibody to hepatocyte growth factor, administered intravenously in patients with relapsed or refractory solid tumors or lymphoma. SCH900105 (AV-299) is being developed in collaboration with Schering-Plough. Under the terms of the agreement, human dosing with SCH900105 (AV-299) triggers a $3 million milestone payment from...

2008-09-23 06:00:11

AVEO Pharmaceuticals, Inc., today announced that it has initiated a Phase 1 clinical trial to evaluate the safety, tolerability and recommended dose of SCH900105 (AV-299), its novel, highly potent antibody to hepatocyte growth factor (HGF), administered intravenously in patients with relapsed or refractory solid tumors or lymphoma. SCH900105 (AV-299) is being developed in collaboration with Schering-Plough (NYSE: SGP). Under the terms of the agreement, human dosing with SCH900105 (AV-299)...

2008-09-23 03:00:27

Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present preclinical results from its recently completed plucked hair biomarker study at the American Association for Cancer Research (AACR) conference, "Molecular Diagnostics in Cancer Therapeutic Development: Fulfilling the Promise of Personalized Medicine" in Philadelphia on 23rd September 2008. This study was completed successfully on a candidate oncology drug from Ortho Biotech Oncology Research and...

2008-08-28 12:01:22

US-based drug discovery company Semafore Pharmaceuticals has announced the discovery of novel multi-targeted kinase inhibitors that demonstrated significant anticancer activity in preclinical studies. Of 50 compounds identified, SF2523 and SF2506 have been chosen for additional evaluation based on their ability to inhibit multiple kinases, including PI3K, mTOR, DNA-PK and PIM-1. Evaluation of SF2523 in a 232 kinase panel screen showed that the compound selectively and potently inhibits...

2008-08-07 09:00:14

DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc. , a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's lead drug candidate, MP-470, for the treatment of glioblastoma multiforme (GBM), an often fatal form of brain cancer. The FDA accepted SuperGen's...

2005-07-18 18:16:31

Scientists now have a more complete understanding of how cancer cells send signals to surrounding tissues to promote development of the blood supply needed to support tumor growth. For the first time, it has been shown that signals expressed by tumor cells can directly interact with the outer membrane of adjacent blood vessel cells and influence growth and development. The research, published in the July issue of Cancer Cell, may provide a new and more efficient target for antiangiogenic...

a5f895132da4f550c085223c0f08a8711
2005-07-18 18:10:00

ANN ARBOR, Mich. - University of Michigan researchers have figured out one more component in cancer cells' aggressive growth---and hope that knowledge can help kill the cells. In the July issue of Cancer Cell, the scientists explain how cancer tumor cells attach themselves to a protein on the surface of cells lining blood vessel walls. When this attachment happens, it tells the cancer cell to grow and develop blood vessels, which feed the cell. Cun-Yu Wang, senior author on the paper, said...

2005-07-18 18:08:45

Scientists supported by the National Institute of Dental and Craniofacial Research (NIDCR), part of the National Institutes of Health, have added a key new piece to the puzzle of how tumor cells induce new blood vessels to form and fuel their abnormal growth, a well-known process called angiogenesis. As published in this month's issue of the journal Cancer Cell, the scientists found that in addition to the well-known strategy of secreting proteins to trigger angiogenesis, tumor cells also...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related